Lung & Respiratory Disease Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

This Phase 4 study from Memorial Sloan Kettering Cancer Center is testing different ways to help smokers quit during lung cancer screening appointments. The goal is to find treatments that are easy for clinics to offer without adding extra work for staff. If successful, this approach could make quitting smoking more accessible and improve health outcomes for adults who smoke and are at risk for lung cancer.

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

This Phase 3 trial evaluated a new pill called AD109 for adults with obstructive sleep apnea (OSA), a condition that disrupts breathing during sleep. Unlike standard treatments such as CPAP machines, this pill aims to simplify therapy and improve sleep quality and daytime function. The study included 660 participants across 64 sites in the United States and has completed with results now available.

Tobacco Cessation at FDNY

This Phase 4 trial tested an enhanced smoking cessation program tailored for high-risk smokers undergoing lung cancer screening. The program combined counseling with medication and used an opt-out enrollment process to encourage more people to try quitting. Conducted at a single U.S. site, the study focused on adults who currently smoke and has published results that may offer new strategies to increase quit rates.

Communicating About Nicotine Reduction in Cigarettes

Conducted by Georgia State University, this study is exploring whether a messaging campaign combined with very low nicotine cigarettes can help adult smokers reduce their nicotine intake. Participants attend weekly visits and complete daily surveys to track changes in smoking behavior. If effective, this approach could provide a new way to support smokers in changing their habits and reducing dependence on nicotine.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

This Phase 3 study in China is testing a new injection treatment for obese adults with moderate-to-severe obstructive sleep apnea who use PAP therapy. The aim is to see if the injection can improve symptoms and quality of life beyond what PAP therapy alone provides. The trial is ongoing, with results expected after a year of treatment.

This week saw important advances in lung and respiratory disease research, especially in smoking cessation and sleep apnea treatments. New strategies to help people quit smoking during lung cancer screening and simplified options for managing sleep apnea may soon offer patients more effective and convenient choices. Trials in nicotine reduction and novel injections are also underway, showing continued progress in this field.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.